具有口服活性的铂类抗肿瘤药物JM216的191Pt标记物的合成。
The synthesis of 191Pt labelled JM216, an orally active platinum anti-tumour agent.
作者信息
Bates P I, Sharma H L, Murrer B A, Bernard C F, McAuliffe C A
机构信息
Department of Medical Biophysics, University of Manchester, Medical School, UK.
出版信息
Appl Radiat Isot. 1997 Apr;48(4):469-76. doi: 10.1016/s0969-8043(96)00267-9.
PMID:9106988
Abstract
The orally active platinum anti-tumour complex JM216[bis-acetatoamminedichlorocyclohexylamineplatinum(IV)] is at present in stage II clinical trials. A procedure for synthesising the complex labelled with 191Pt or 188Pt at the platinum centre has been developed. The purity (shown by HPLC) is 98% and the specific activity (0.3-0.4 Ci/kg) is enough for in vivo and in vitro studies.
摘要
口服活性铂抗肿瘤复合物JM216[双乙酸氨基二氯环己胺铂(IV)]目前正处于II期临床试验阶段。已开发出一种在铂中心标记191Pt或188Pt的该复合物的合成方法。纯度（通过高效液相色谱法显示）为98%，比活度（0.3 - 0.4居里/千克）足以用于体内和体外研究。
Zotero 插件